AbbVie Inc., US00287Y1091

AbbVie stock: Barclays maintains Buy rating with USD 335 target

Published on 11/17/2026 at 12:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Barclays maintained its Buy rating on AbbVie stock in a Monday research report. The call adds an analyst perspective as investors assess pipeline progress.

Analyst view adds a fresh reference

  • Barclays maintained its Buy rating on AbbVie in a report published Monday.
  • The research view comes as investors assess pipeline progress and recent quarterly growth.
AbbVie Inc., US00287Y1091, Illustration mit AI erstellt.

On Monday, November 16, Barclays maintained its Buy rating on AbbVie and set a USD 335 price target, according to Markets Insider. The report identified Emily Field as the Barclays analyst covering the company.

AbbVie stock traded at 266.85 euros on Lang & Schwarz at 12:36 CET on Tuesday, November 17. The quote provides a live trading reference for the European listing while the analyst target is expressed in US dollars for AbbVie's primary US market.

Pipeline progress remains central

The analyst view arrives as AbbVie works to extend growth beyond its established immunology franchise. Skyrizi and Rinvoq remain important drivers of the company's pharmaceutical portfolio, while the longer-term investment case also depends on progress across neuroscience, oncology and other development programs.

Recent company developments have kept pipeline execution in focus. AbbVie has reported positive late-stage QULIPTA results in migraine prevention and has expanded its early-stage immunology pipeline through licensing activity. Those developments support the breadth of the portfolio, but future commercial relevance will depend on regulatory progress, launches and prescription trends.

Quarterly growth sets the backdrop

AbbVie reported third-quarter revenue of USD 17.4 billion and adjusted earnings per share of USD 3.82, according to the report's summary of the company's latest results. Revenue increased 10.3% from the year-earlier quarter, with growth from newer products helping offset continued pressure on Humira from biosimilar competition.

For investors, the Barclays call offers a fresh sell-side assessment alongside the company's operating progress. The target is not a forecast of a guaranteed market price, while the gap between a research target and a traded quote can change with earnings, clinical news, regulation and broader healthcare sentiment.

AbbVie Inc. stock facts

  • Company: AbbVie Inc.
  • ISIN: US00287Y1091
  • WKN: A1J84E
  • Ticker: ABBV
  • Primary listing: NYSE
  • Lang & Schwarz quote: 266.85 euros, Tuesday, November 17, 2026, 12:36 CET

US stocks remain the broader market backdrop for AbbVie, with the S&P 500 providing the relevant benchmark context for the company's primary market.

More news and analyses on AbbVie stock

Disclaimer...
en | US00287Y1091 | ABBVIE INC. | boerse | 70526389 | bgmi